Patents by Inventor Samir P. Tabash

Samir P. Tabash has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR REDUCING PARATHYROID LEVELS
    Publication number: 20230346804
    Abstract: Methods and compositions for reducing serum parathyroid levels in, for example, chronic kidney disease patients are disclosed. In these methods, an effective amount of a modified release formulation of 25-hydroxyvitamin D is orally administered to a patient suffering from secondary hyperparathyroidism to lower the patient's serum intact parathyroid hormone (iPTH) level, while avoiding a surge in serum total 25-hydroxyvitamin D.
    Type: Application
    Filed: May 1, 2023
    Publication date: November 2, 2023
    Inventors: Eric J. Messner, P. Martin Petkovich, Jay A. White, Samir P. Tabash, Joel Z. Melnick, Charles W. Bishop
  • Method of treating vitamin D insufficiency and deficiency
    Patent number: 11752158
    Abstract: The invention relates to methods and compositions for reducing toxicity associated with administration of vitamin D3, its 25-hydroxylated and 1-hydroxylated forms, and analogs thereof.
    Type: Grant
    Filed: April 25, 2008
    Date of Patent: September 12, 2023
    Assignee: EIRGEN PHARMA LTD.
    Inventors: P. Martin Petkovich, Christian F. Helvig, Samir P. Tabash
  • Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
    Patent number: 11738033
    Abstract: Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: August 29, 2023
    Assignee: EIRGEN PHARMA LTD.
    Inventors: P. Martin Petkovich, Joel Z. Melnick, Jay A. White, Samir P. Tabash, Charles W. Bishop, Susan Peers, Stephen A. Strugnell
  • Methods and compositions for reducing parathyroid levels
    Patent number: 11672809
    Abstract: Methods and compositions for reducing serum parathyroid levels in, for example, chronic kidney disease patients are disclosed. In these methods, an effective amount of a modified release formulation of 25-hydroxy vitamin D is orally administered to a patient suffering from secondary hyperparathyroidism to lower the patient's serum intact parathyroid hormone (iPTH) level, while avoiding a surge in serum total 25-hydroxy vitamin D.
    Type: Grant
    Filed: March 29, 2011
    Date of Patent: June 13, 2023
    Assignee: EIRGEN PHARMA LTD.
    Inventors: Eric J. Messner, P. Martin Petkovich, Jay A. White, Samir P. Tabash, Joel Z. Melnick, Charles W. Bishop
  • STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING SAME
    Publication number: 20220125806
    Abstract: A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation can comprise one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a stabilizing compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.
    Type: Application
    Filed: January 6, 2022
    Publication date: April 28, 2022
    Inventors: Jay A. White, Samir P. Tabash, Sammy A. Agudoawu, Joel Z. Melnick
  • Stabilized modified release Vitamin D formulation and method of administering same
    Patent number: 11253528
    Abstract: A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: February 22, 2022
    Assignee: EIRGEN PHARMA LTD.
    Inventors: Jay A. White, Samir P. Tabash, Sammy A. Agudoawu, Joel Z. Melnick
  • Methods for controlled release oral dosage of a vitamin D compound
    Patent number: 11154509
    Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: October 26, 2021
    Assignees: EIRGEN PHARMA LTD., OPKO RENAL, LLC
    Inventors: Charles W. Bishop, Samir P. Tabash, Sammy A. Agudoawu, Jay A. White, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich
  • Adjunctive Therapy With 25-Hydroxyvitamin D And Articles Therefor
    Publication number: 20210260079
    Abstract: Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.
    Type: Application
    Filed: May 11, 2021
    Publication date: August 26, 2021
    Inventors: P. Martin Petkovich, Joel Z. Melnick, Jay A. White, Samir P. Tabash, Charles W. Bishop, Susan Peers, Stephen A. Strugnell
  • Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
    Patent number: 11007205
    Abstract: Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: May 18, 2021
    Assignee: EIRGEN PHARMA LTD.
    Inventors: P. Martin Petkovich, Joel Z. Melnick, Jay A. White, Samir P. Tabash, Charles W. Bishop, Susan Peers, Stephen A. Strugnell
  • ADJUNCTIVE THERAPY WITH 25-HYDROXYVITAMIN D
    Publication number: 20200253988
    Abstract: Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.
    Type: Application
    Filed: April 27, 2020
    Publication date: August 13, 2020
    Applicant: OPKO IRELAND GLOBAL HOLDINGS, LTD
    Inventors: P. Martin Petkovich, Joel Z. Melnick, Jay A. White, Samir P. Tabash, Charles W. Bishop, Susan Peers, Stephen A. Strugnell
  • ADJUNCTIVE THERAPY WITH 25-HYDROXYVITAMIN D AND ARTICLES THEREFOR
    Publication number: 20200101089
    Abstract: Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.
    Type: Application
    Filed: December 2, 2019
    Publication date: April 2, 2020
    Inventors: P. Martin Petkovich, Joel Z. Melnick, Jay A. White, Samir P. Tabash, Charles W. Bishop, Susan Peers, Stepehn A. Strugnell
  • STABILIZED MODIFIED RELEASE VITAMIN D FORMULATION AND METHOD OF ADMINISTERING SAME
    Publication number: 20190374555
    Abstract: A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.
    Type: Application
    Filed: June 21, 2019
    Publication date: December 12, 2019
    Inventors: Jay A. White, Samir P. Tabash, Sammy A. Agudoawu, Joel Z. Melnick
  • Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
    Patent number: 10493084
    Abstract: Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.
    Type: Grant
    Filed: January 9, 2019
    Date of Patent: December 3, 2019
    Assignee: OPKO IRELAND GLOBAL HOLDINGS, LTD.
    Inventors: P. Martin Petkovich, Joel Z. Melnick, Jay A. White, Samir P. Tabash, Charles W. Bishop, Susan Peers, Stephen A. Strugnell
  • Stabilized modified release vitamin D formulation and method of administering same
    Patent number: 10357502
    Abstract: A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: July 23, 2019
    Assignee: OPKO IRELAND GLOBAL HOLDINGS, LTD.
    Inventors: Jay A. White, Samir P. Tabash, Sammy A. Agudoawu, Joel Z. Melnick
  • Stabilized modified release vitamin D formulation and method of administering same
    Patent number: 10350224
    Abstract: A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: July 16, 2019
    Assignee: OPKO IRELAND GLOBAL HOLDINGS, LTD.
    Inventors: Jay A. White, Samir P. Tabash, Sammy A. Agudoawu, Joel Z. Melnick
  • Stabilized modified release vitamin D formulation and method of administering same
    Patent number: 10300078
    Abstract: A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: May 28, 2019
    Assignee: OPKO IRELAND GLOBAL HOLDINGS, LTD.
    Inventors: Jay A. White, Samir P. Tabash, Sammy A. Agudoawu, Joel Z. Melnick
  • Adjunctive Therapy with 25-Hydroxyvitamin D and Articles Therefor
    Publication number: 20190142847
    Abstract: Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.
    Type: Application
    Filed: January 9, 2019
    Publication date: May 16, 2019
    Inventors: P. Martin Petkovich, Joel Z. Melnick, Jay A. White, Samir P. Tabash, Charles W. Bishop, Susan Peers, Stephen A. Strugnell
  • Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
    Patent number: 10220047
    Abstract: Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: March 5, 2019
    Assignee: OPKO IRELAND GLOBAL HOLDINGS, LTD.
    Inventors: P. Martin Petkovich, Joel Z. Melnick, Jay A. White, Samir P. Tabash, Charles W. Bishop, Susan Peers, Stephen A. Strugnell
  • Stabilized Modified Release Vitamin D Formulation and Method of Administering Same
    Publication number: 20180271885
    Abstract: A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 27, 2018
    Inventors: Jay A. White, Samir P. Tabash, Sammy A. Agudoawu, Joel Z. Melnick
  • Stabilized Modified Release Vitamin D Formulation and Method of Administering Same
    Publication number: 20180271884
    Abstract: A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.
    Type: Application
    Filed: May 25, 2018
    Publication date: September 27, 2018
    Inventors: Jay A. White, Samir P. Tabash, Sammy A. Agudoawu, Joel Z. Melnick